An update on the safety and efficacy of decitabine in the treatment of myelodysplastic syndromes

References

• VardimanJWThieleJArberDAThe 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changesBlood200911493795119357394
   PubMed Web of Science ®Google Scholar
• TefferiAVardimanJWMyelodysplastic syndromesN Engl J Med20093611872188519890130
   PubMed Web of Science ®Google Scholar
• MaXDoesMRazaAMayneSTMyelodysplastic syndromes: incidence and survival in the United StatesCancer20071091536154217345612
   PubMed Web of Science ®Google Scholar
• SanzGFSanzMAGreenbergPLPrognostic factors and scoring systems in myelodysplastic syndromesHaematologica1998833583689592987
   PubMed Web of Science ®Google Scholar
• GreenbergPCoxCLeBeauMMInternational scoring system for evaluating prognosis in myelodysplastic syndromesBlood199789207920889058730
   PubMed Web of Science ®Google Scholar
• WijermansPWLubbertMVerhoefGKlimekVBoslyAAn epigenetic approach to the treatment of advanced MDS; the experience with the DNA demethylating agent 5-aza-2’-deoxycytidine (decitabine) in 177 patientsAnn Hematol200584Suppl 191716211386
   PubMed Web of Science ®Google Scholar
• IssaJPKantarjianHMTargeting DNA methylationClin Cancer Res2009153938394619509174
   PubMed Web of Science ®Google Scholar
• GoreSDJonesCKirkpatrickPDecitabineNat Rev Drug Discov2006589189217117522
   PubMed Web of Science ®Google Scholar
• KantarjianHIssaJPRosenfeldCSDecitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized studyCancer20061061794180316532500
   PubMed Web of Science ®Google Scholar
• StresemannCLykoFModes of action of the DNA methyltransferase inhibitors azacytidine and decitabineInt J Cancer200812381318425818
   PubMed Web of Science ®Google Scholar
• YooCBJeongSEggerGDelivery of 5-aza-2’-deoxycytidine to cells using oligodeoxynucleotidesCancer Res2007676400640817616700
   PubMed Web of Science ®Google Scholar
• KihslingerJEGodleyLAThe use of hypomethylating agents in the treatment of hematologic malignanciesLeuk Lymphoma2007481676169517786703
   PubMed Web of Science ®Google Scholar
• BlumWKlisovicRBHackansonBPhase I study of decitabine alone or in combination with valproic acid in acute myeloid leukemiaJ Clin Oncol2007253884389117679729
   PubMed Web of Science ®Google Scholar
• GoreSDBaylinSSugarECombined DNA methyltransferase and histone deacetylase inhibition in the treatment of myeloid neoplasmsCancer Res2006666361636916778214
   PubMed Web of Science ®Google Scholar
• FigueroaMESkrabanekLLiYMDS and secondary AML display unique patterns and abundance of aberrant DNA methylationBlood20091143448345819652201
   PubMed Web of Science ®Google Scholar
• ChesonBDBennettJMKantarjianHReport of an international working group to standardize response criteria for myelodysplastic syndromesBlood2000963671367411090046
   PubMed Web of Science ®Google Scholar
• ChesonBDGreenbergPLBennettJMClinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasiaBlood200610841942516609072
   PubMed Web of Science ®Google Scholar
• RivardGEMomparlerRLDemersJPhase I study on 5-aza-2’-deoxycytidine in children with acute leukemiaLeuk Res198154534626173545
   PubMed Web of Science ®Google Scholar
• MomparlerRLRivardGEGygerMClinical trial on 5-aza-2’-deoxycytidine in patients with acute leukemiaPharmacol Ther1985302772862433702
   PubMed Web of Science ®Google Scholar
• WillemzeRArchimbaudEMuusPPreliminary results with 5-aza-2’-deoxycytidine (DAC)-containing chemotherapy in patients with relapsed or refractory acute leukemia. The EORTC Leukemia Cooperative GroupLeukemia19937Suppl 149507683357
   PubMed Web of Science ®Google Scholar
• ZagonelVLo ReGMarottaG5-Aza-2’-deoxycytidine (Decitabine) induces trilineage response in unfavourable myelodysplastic syndromesLeukemia19937Suppl 130357683354
   PubMed Web of Science ®Google Scholar
• WijermansPLubbertMVerhoefGLow-dose 5-aza-2’-deoxycytidine, a DNA hypomethylating agent, for the treatment of high-risk myelodysplastic syndrome: a multicenter phase II study in elderly patientsJ Clin Oncol20001895696210694544
   PubMed Web of Science ®Google Scholar
• KantarjianHMO’BrienSHuangXSurvival advantage with decitabine versus intensive chemotherapy in patients with higher risk myelodysplastic syndrome: comparison with historical experienceCancer20071091133113717315156
   PubMed Web of Science ®Google Scholar
• WijermansPSuciuSBailaLLow dose decitabine versus best supportive care in elderly patients with intermediate or high risk MDS not eligible for intensive chemotherapy: final results of the randomized phase iii study (06011) of the EORTC Leukemia and German MDS Study Groups. 50th American Society of Hematology Annual Meeting. San Francisco, CaliforniaBlood2008226
   Google Scholar
• KantarjianHOkiYGarcia-ManeroGResults of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemiaBlood2007109525716882708
   PubMed Web of Science ®Google Scholar
• KantarjianHMO’BrienSShanJUpdate of the decitabine experience in higher risk myelodysplastic syndrome and analysis of prognostic factors associated with outcomeCancer200710926527317133405
   PubMed Web of Science ®Google Scholar
• RavandiFIssaJPGarcia-ManeroGSuperior outcome with hypomethylating therapy in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome and chromosome 5 and 7 abnormalitiesCancer20091155746575119795507
   PubMed Web of Science ®Google Scholar
• SteensmaDPBaerMRSlackJLMulticenter study of decitabine administered daily for 5 days every 4 weeks to adults with myelodysplastic syndromes: the alternative dosing for outpatient treatment (ADOPT) trialJ Clin Oncol2009273842384819528372
   PubMed Web of Science ®Google Scholar
• RuterBWijermansPWLubbertMSuperiority of prolonged low-dose azanucleoside administration? Results of 5-aza-2’-deoxycytidine retreatment in high-risk myelodysplasia patientsCancer20061061744175016532502
   PubMed Web of Science ®Google Scholar
• GreenbergPLAttarEBattiwallaMMyelodysplastic syndromesJ Natl Compr Canc Netw2008690292618926100
   PubMedGoogle Scholar
• GermingUKundgenAGattermannNRisk assessment in chronic myelomonocytic leukemia (CMML)Leuk Lymphoma2004451311131815359628
   PubMed Web of Science ®Google Scholar
• WijermansPWKrulderJWHuijgensPCNevePContinuous infusion of low-dose 5-Aza-2’-deoxycytidine in elderly patients with high-risk myelodysplastic syndromeLeukemia199711159001409
   PubMed Web of Science ®Google Scholar
• WijermansPWRuterBBaerMRSlackJLSabaHILubbertMEfficacy of decitabine in the treatment of patients with chronic myelomonocytic leukemia (CMML)Leuk Res20083258759117881052
   PubMed Web of Science ®Google Scholar
• AribiABorthakurGRavandiFActivity of decitabine, a hypomethylating agent, in chronic myelomonocytic leukemiaCancer200710971371717219444
   PubMed Web of Science ®Google Scholar
• ScottBDeegHJHemopoietic cell transplantation as curative therapy of myelodysplastic syndromes and myeloproliferative disordersBest Pract Res Clin Haematol20061951953316781487
   PubMed Web of Science ®Google Scholar
• KrogerNEpigenetic modulation and other options to improve outcome of stem cell transplantation in MDSHematology Am Soc Hematol Educ Program2008606719074059
   PubMedGoogle Scholar
• LubbertMHartmutBRuterBMertelsmannRFinkeJNon-intensive AML/MDS treatment with low-dose decitabine prior to reduced-intensity conditioning (RIC) and allogeneic blood stem cell transplantation of older patients. 48th American Society of Hematology Annual Meeting. Orlando, FLBlood20065257
   Google Scholar
• De PaduaSde LimaMKantarjianHOutcome of allogeneic stem cell transplantation after hypomethylating therapy with 2’-deoxy-5 azacytidine for patients with myelodysplastic syndrome. 49th American Society of Hematology Annual Meeting. Atlanta, GABlood20071468
   Google Scholar
• CzibereAGraefTJL5-Azacitidine in combination with donor lymphocyte infusions for the treatment of patients with MDS or AML relapsing after allogeneic stem cell Transplantation. 48th American Society of Hematology Annual Meeting. Orlando, FLBlood20065341
   Google Scholar
• de LimaMPaduaLGiraltSA dose and schedule finding study of maintenance therapy with low-dose 5-azacitidine (AZA) after allogeneic hematopoietic stem cell transplantation (HSCT) for high-risk AML or MDS. 49th American Society of Hematology Annual MeetingBlood20073012
   Google Scholar
• De Padua SilvaLde LimaMKantarjianHFeasibility of allo-SCT after hypomethylating therapy with decitabine for myelodysplastic syndromeBone Marrow Transplant20094383984319151791
   PubMed Web of Science ®Google Scholar
• JainNMattiuzziGNCortesJBenefit of anti-infectious prophylaxis in patients with acute myeloid leukemia or high-risk myelodysplastic syndrome receiving frontline “targeted therapy”. 49th American Society of Hematology Annual Meeting. Atlanta, GeorgiaBlood20072858
   Google Scholar
• ChenCCGauJPYouJYDecitabine-induced effusionsLeuk Res200933e150e15119157543
   PubMedGoogle Scholar
• VasuTSCavallazziRHiraniAMarikPEA 64-year-old male with fever and persistent lung infiltrateRespir Care2009541263126519712502
   PubMed Web of Science ®Google Scholar
• FenauxPMuftiGJHellstrom-LindbergEEfficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III studyLancet Oncol20091022323219230772
   PubMed Web of Science ®Google Scholar
• BorthakurGAhdabSERavandiFActivity of decitabine in patients with myelodysplastic syndrome previously treated with azacitidineLeuk Lymphoma20084969069518398735
   PubMed Web of Science ®Google Scholar
• GurionRVidalLGafter-GviliA5-azacitidine prolongs overall survival in patients with myelodysplastic syndrome – systematic review and meta-analysisHaematologica2009
   Web of Science ®Google Scholar
• KumarAListAFMhaskarRDjulbegovicBEfficacy of hypo-methylating agents in the treatment of myelodysplastic syndromes: a systematic review and meta-analysis of randomized controlled trials. 50th American Society of Hematology Annual Meeting. San Francisco, CaliforniaBlood20083632
   Google Scholar
• KumarAListAFHozoIKomrokjiRDjulbegovicBDecitabine versus 5-azacitidine for the treatment of myelodysplastic syndrome: adjusted indirect meta-analysisHaematologica2009
   Web of Science ®Google Scholar
• SilvermanLRDemakosEPPetersonBLRandomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group BJ Clin Oncol2002202429244012011120
   PubMed Web of Science ®Google Scholar
• CameronEEBachmanKEMyohanenSHermanJGBaylinSBSynergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancerNat Genet1999211031079916800
   PubMed Web of Science ®Google Scholar
• SuzukiHGabrielsonEChenWA genomic screen for genes upregulated by demethylation and histone deacetylase inhibition in human colorectal cancerNat Genet20023114114911992124
   PubMed Web of Science ®Google Scholar
• Garcia-ManeroGKantarjianHMSanchez-GonzalezBPhase 1/2 study of the combination of 5-aza-2’-deoxycytidine with valproic acid in patients with leukemiaBlood20061083271327916882711
   PubMed Web of Science ®Google Scholar
• YangHHoshinoKSanchez-GonzalezBKantarjianHGarcia-ManeroGAntileukemia activity of the combination of 5-aza-2’-deoxycytidine with valproic acidLeuk Res20052973974815927669
   PubMed Web of Science ®Google Scholar
• RavandiFFaderlSThomasDPhase I study of suberoylanilide hydroxamic acid (SAHA) and decitabine in patients with relapsed, refractory or poor prognosis leukemia. 49th American Society of Hematology Annual Meeting. New Orleans, LouisianaBlood2007897
   Google Scholar